Lantheus Holdings, Inc. (NASDAQ:LNTH) Stock Has Average Target Price of $108.11

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have received an average rating of “Hold” from the fourteen ratings firms that are currently covering the company, MarketBeat.com reports. Ten analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $108.11.

LNTH has been the topic of a number of research reports. William Blair set a $102.50 price target on shares of Lantheus in a research note on Monday, August 3rd. Citizens Jmp restated a “market outperform” rating and set a $115.00 price objective on shares of Lantheus in a report on Monday, June 29th. CJS Securities lowered Lantheus from a “market outperform” rating to a “market perform” rating in a research note on Tuesday, August 4th. TD Cowen cut Lantheus from a “buy” rating to a “hold” rating and dropped their price target for the stock from $110.00 to $102.50 in a report on Monday, August 3rd. Finally, Leerink Partners set a $102.50 price target on Lantheus in a research note on Monday, August 3rd.

Lantheus Trading Up 0.3%

Lantheus stock opened at $99.96 on Thursday. Lantheus has a 52 week low of $49.67 and a 52 week high of $111.86. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06. The stock has a market capitalization of $6.52 billion, a P/E ratio of 24.14 and a beta of -0.06. The stock has a 50-day simple moving average of $100.71 and a 200 day simple moving average of $96.12.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, August 6th. The medical equipment provider reported $1.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.30 by $0.25. Lantheus had a return on equity of 28.10% and a net margin of 17.69%.The firm had revenue of $388.18 million for the quarter, compared to analyst estimates of $363.23 million. During the same quarter in the prior year, the company earned $1.57 earnings per share. The business’s revenue for the quarter was up 2.7% compared to the same quarter last year. Analysts expect that Lantheus will post 4.5 earnings per share for the current year.

Institutional Investors Weigh In On Lantheus

A number of institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new stake in Lantheus in the 2nd quarter worth about $575,628,000. Reinhart Partners LLC. increased its holdings in shares of Lantheus by 2.2% during the second quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock worth $177,437,000 after purchasing an additional 34,501 shares during the period. Carmignac Gestion raised its position in shares of Lantheus by 0.9% in the second quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after buying an additional 12,100 shares in the last quarter. Norges Bank acquired a new stake in shares of Lantheus in the fourth quarter valued at approximately $76,197,000. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Lantheus by 440.3% in the second quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after buying an additional 582,661 shares during the period. Institutional investors own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.